Ciputra Development Tbk vs Merck Tbk. — how do they compare? Ciputra Development Tbk trades at Rp575 (market cap 10.38T, 5.49M 24h volume), while Merck Tbk. trades at Rp3,840 (market cap 1.7T, 13.4K 24h volume). The key difference: Ciputra Development Tbk is far larger — about 6.1× Merck Tbk.'s market cap, and Ciputra Development Tbk is more actively traded (5.49M versus 13.4K). Which is the better fit depends on your goals.
| CTRA | MERK | |
|---|---|---|
Market Cap | 10.38T | 1.7T |
Volume | 5.49M | 13.4K |
Lot | 54.91K | 134 |
Turnover | 3.15B | 51.3M |
Average Price | 573.83 | 3,828.51 |
Value | 3.15B | 51.3M |
Indicative Equilibrium Price | 565 | 3,850 |
Indicative Equilibrium Volume | 819 | 1 |
Trailing returns across standard periods
Latest headlines on both assets
PT Ciputra Development Tbk (the Company) was established in the Republic of Indonesia originally under the name PT Citra Habitat Indonesia based on notarial deed No. 22 dated October 22, 1981. Ciputra Developments main interest is in residential and township developments which account for approximately 90% of the companies total sales. The company has nine flagship development projects.
Read more on CTRA →PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Read more on MERK →